

1103326-0250 (CON)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**RECEIVED
CENTRAL FAX CENTER***Free Purpose
Only*

In re Application of : Depui, et al.
 Serial No. : 10/620,000
 Filed : July 14, 2003
 For : ORAL PHARMACEUTICAL DOSAGE
 FORMS COMPRISING A PROTON
 PUMP INHIBITOR AND A NSAID
 Examiner : Spear, J.
 Group Art Unit : 1615

JAN 20 2005

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. 1.8

I hereby certify that this paper is being facsimile-
 transmitted to the U.S. Patent and Trademark Office
 on 20 January 2005
 at the facsimile number 703-872-9306.

John M. Genova

32,224

Agent Name

PTO Reg. No.

Signature

Date of Signature

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

ATTENTION: Examiner James Spear
DATE: 20 January 2005
NUMBER OF PAGES: 3
FAX NUMBER: 703-872-9306

TERMINAL DISCLAIMER

Sir:

AstraZeneca, a corporation created and existing under the laws of Sweden, and having a business address at S-151 85 Södertälje, Sweden, hereby through its undersigned agent, who is empowered to act on behalf of AstraZeneca, represents that AstraZeneca is the owner of the entire right, title and interest of the above-identified U.S. Patent Application Serial No. 10/620,000 and US 6,613,354 by Assignment recorded on February 13, 1997, at Reel 9029/Reel 0319. The originally recorded assignment is in the name of Astra Aktiebolag. A change of corporate name from Astra Aktiebolag to AstraZeneca was recorded on January 18, 2002 at Reel 012494, Frame 0470.

NEWYORK 4609794 11 1409794 1 100X1 (28)

02/18/2005 08:52:22 00000000 131703 10620000
 01 FEB1814 120.00 148

AstraZeneca, by its undersigned agent, states that all evidentiary documents have been reviewed and certifies that, to the best of its knowledge and belief, title to U.S. Patent Application Serial No. 10/620,000 and US 6,613,354 is in AstraZeneca. The inventions claimed in U.S. Patent Application Serial No. 10/620,000 and US 6,613,354 were commonly owned by AstraZeneca at the time the later invention was made.

AstraZeneca hereby disclaims, except as provided below, the terminal portion of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term as defined in 35 U.S.C. §§154 to 156 and 173 of US 6,613,354 as presently shortened by any terminal disclaimer. AstraZeneca hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period it and US 6,613,354 are commonly owned. This agreement runs with any patent granted on the above-identified application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§154 to 156 and 173 of US 6,613,354, as presently shortened by terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims canceled by a reexamination certificate, is reissued or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Authorization is hereby given to charge Deposit Account No. 23-1703 in the amount of One Hundred and Thirty Dollars (\$130.00) to cover the fee as required by 37 C.F.R. §1.20(d) and for any other fee that may be required in connection with this communication.

Dated: January 20, 2005

Respectfully submitted,



John M. Genova

Reg. No. 32,224

Client No. 007470

Attorney Direct Dial (212) 819-8832